Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04339140 | Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer | completed | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04501913 | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes | completed | — | 22 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06007586 | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients | completed | Phase 3 | 143 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06870539 | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment | completed | — | 49 | Mayo ClinicOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03249142 | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer(INeOV) | completed | Phase 1 / Phase 2 | 69 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT02326064 | Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4(TORCH) | completed | — | 221 | Centre Hospitalier Departemental VendeeOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05472532 | Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)(INOVOLINE) | completed | N/A | 101 | Hospices Civils de LyonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06925113 | A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan(HERGYN) | completed | — | 509 | Daiichi SankyoINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05523700 | Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)(VIRGO) | completed | N/A | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 178 | Corcept TherapeuticsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT05446870 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 1, 2025 | clinicaltrials |
| NCT03275506 | PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .(NEOPEMBROV) | completed | Phase 2 | 91 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | completed | Phase 3 | 421 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04374630 | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian(PROFECTA-II) | completed | Phase 2 | 150 | Laekna LimitedINDUSTRY | 2 | Sep 10, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03085225 | Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.(TRAMUNE) | completed | Phase 1 | 40 | Institut BergoniéOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154966 | Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy(GYM-TASTE) | completed | — | 102 | Ankara Etlik City HospitalOTHER_GOV | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05815862 | Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer | completed | Phase 2 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01767675 | Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 99 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06958068 | Sexual Health Integration in Treatment of Gynecological Oncology(SHIFT-GO) | completed | — | 324 | Medical University of SilesiaOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | completed | Phase 1 | 136 | Sutro Biopharma, Inc.INDUSTRY | 2 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT03831230 | Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response(OVAREX) | completed | — | 250 | Centre Francois BaclesseOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05047926 | Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | N/A | 90 | Mayo ClinicOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07105553 | Glove Compression for Chemotherapy-Induced Neuropathy(NEURO-GLOVE) | completed | N/A | 76 | Ankara Etlik City HospitalOTHER_GOV | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06048367 | Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor(CNSI-Fe(II)) | completed | Phase 1 | 19 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03395080 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma(P204) | completed | Phase 2 | 111 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04458597 | Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. | completed | N/A | 23 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03267589 | Trial in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 25 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 29, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT03534453 | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy(L-MOCA) | completed | Phase 3 | 229 | AstraZenecaINDUSTRY | 2 | Jul 10, 2025 | clinicaltrials |
| NCT03863860 | A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients | completed | Phase 3 | 252 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT02821793 | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer(PRIORITY) | completed | — | 346 | Institut BergoniéOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | completed | Phase 1 | 19 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04608409 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | completed | Phase 1 | 16 | Frederick R. Ueland, M.D.OTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2025source: clinicaltrials